Ophtesic (Anhydrous Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on sensory nerve fibers in the eye, preventing the initiation and propagation of pain signals. This stabilizes neuronal membranes and produces rapid, reversible loss of sensation on the ocular surface.

The specific dose and administration schedule for Ophtesic are determined by the prescribing clinician based on the procedure, patient characteristics, and clinical judgment. Healthcare professionals should follow the product labeling and institutional protocols.

Safety data for lidocaine ophthalmic use in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the prescriber should evaluate each case individually.

To request Ophtesic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Ophtesic contains lidocaine, an amide‑type local anesthetic with a rapid onset and short duration, similar to other lidocaine‑based eye drops. Compared with proparacaine or tetracaine, lidocaine offers comparable efficacy but may have a slightly different safety profile regarding corneal toxicity, making choice dependent on clinician preference and patient factors.

Ophtesic should be stored below 25 °C in its original container, protected from moisture and light. Do not freeze the product. Once opened, use according to the label’s recommended period to maintain sterility and potency.

Ophtesic is applied topically to the ocular surface as a sterile drop. The prescriber determines the number of drops and timing based on the intended procedure. Proper aseptic technique should be used to avoid contamination.

Serious risks include allergic reactions such as angioedema or anaphylaxis, corneal epithelial toxicity leading to ulceration, and systemic toxicity if excessive amounts are absorbed. Patients should be monitored for signs of severe irritation, visual changes, or systemic symptoms.

Ophtesic should not be used in individuals with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, in eyes with active severe infection, or in patients with compromised corneal epithelium where further toxicity could be detrimental.